Autopsy report · NCT03075553

Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

“due to poor response”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 2 years before it stopped.
• 12 participants enrolled.
• Results were posted on the registry 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Mayo Clinic

Sponsor type

University, hospital or other

Conditions

Blastic Plasmacytoid Dendritic Cell Neoplasm; Hepatosplenic T-Cell Lymphoma; HTLV-1 Infection; NK-Cell Lymphoma, Unclassifiable; Primary Systemic Anaplastic Large Cell Lymphoma, ALK-Negative; Recurrent Adult T-Cell Leukemia/Lymphoma

Interventions

Laboratory Biomarker Analysis; Nivolumab

Participants

12

Sites

1

Countries

United States

Trials that died the same way

• A Clinical Investigation of the M2a- 38™ Hip System
  “due to low follow up” (59% match in meaning)
• Myocet Plus Endoxan for Older Patients With Breast Cancer
  “Due to poor accrual” (57% match in meaning)
• To Study and Compare the Clinical Course and Development of Organ Failure in Severe Acute Hepatitis Without Ascites, Non-cirrhotic and Cirrhotic Patients With Ascites [Acute on Chronic Liver Failure] and Acute Deterioration of Previously Decompensated Cirrhosis.
  “Due to lack of funds” (56% match in meaning)
• Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
  “Due to business reasons” (55% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.